Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMY)
Filing Type: Form 8-K (Current Report)
Date of Report: April 18, 2022
Subject: Modification of non-GAAP financial presentation and preliminary Q1 2022 earnings impact.
Key Financial Metrics and Presentation Changes
Effective Q1 2022, the Company is altering its non-GAAP financial measures following discussions with the SEC. Significant R&D charges and income from upfront or contingent milestone payments related to asset acquisitions or third-party IP licensing will no longer be excluded from non-GAAP results. These items will be presented in a new line item labeled Acquired IPRD. Prior periods (2020, 2021) have been revised to conform to this new presentation.
- Q1 2022 Preliminary Impact: GAAP and non-GAAP earnings per share are expected to include a net negative impact of approximately $0.10 per share due to Acquired IPRD charges and licensing income.
- Financial Status: Results for the quarter ended March 31, 2022, are preliminary and subject to final closing procedures.
Material Changes Versus Prior Period
The primary material change is the reclassification of specific R&D charges from R&D expense to the new Acquired IPRD line item. This change affects the comparability of non-GAAP results between the current period and previously reported periods, necessitating the revision of historical data for 2020 and 2021 to ensure consistency.
Guidance, Outlook, and Risks
Outlook: The Company anticipates the $0.10 per share negative impact for Q1 2022 but notes that final results may differ from this preliminary estimate.
Risks and Contingencies:
- Final Q1 2022 results are subject to the quarter-end closing process, including management and audit committee review.
- Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from projections.
- The filing explicitly states that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into future filings unless specifically provided.
Investor Verification Checklist
- Verify the final Q1 2022 earnings per share once the financial statement closing is complete to confirm the $0.10 impact estimate.
- Review Exhibit 99.1 for the detailed reconciliation of revised GAAP and non-GAAP results for 2020 and 2021.
- Monitor future filings for the finalized definition and scope of the new "Acquired IPRD" line item.
- Check subsequent 10-Q filings for any adjustments to the preliminary Q1 2022 figures.